Xeljanz Heart Risk MDL — Pfizer Faces Claims Over JAK Inhibitor Cardiac Side Effects

Pfizer's Xeljanz (tofacitinib), a JAK inhibitor originally approved to treat rheumatoid arthritis, has become the subject of a federal multidistrict...

Pfizer's Xeljanz (tofacitinib), a JAK inhibitor originally approved to treat rheumatoid arthritis, has become the subject of a federal multidistrict...